Semaglutide belongs to a group of diabetes medications called glucagon-like peptide 1 (GLP-1) receptor agonists
Adverse reactions to drugs BNF Medicines Guidance
Mahaffey, K.W., et al., Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
Limit processed foods such as junk foods, refined sugars, and frozen meals
Ileus or bowel obstruction Gallbladder disease and gallstones Pancreatitis and pancreatic injury Dehydration , electrolyte imbalances , and kidney strain Weight loss outside expected ranges or malnutrition in some cases, including individuals using these drugs, such as Ozempic, for weight loss Vision loss and rare visual conditions such as NAION , with some plaintiffs reporting symptoms consistent with naion even before clear diagnosis Concerns over thyroid Ccell tumors noted in animal studies The lawsuits generally claim that manufacturers, including Novo Nordisk, failed to provide adequate warnings about drugs like Ozempic, promoted offlabel use for weight loss without proper risk disclosures, and did not update labels or prescriber communications quickly enough as reports of side effects and other injuries came in
pricing changes will have only a low single digit negative impact on its 2026 global sales growth
